Clinically, we often observe that oral BPC-157 offers superior outcomes for patients with GI inflammation, bloating, food sensitivities, or irritable bowel symptoms
Protecting the now-vulnerable peptide is an ongoing process
It was first approved by the FDA in 2006 and is used to improve glycemic control in people with type 2 diabetes mellitus
Weight loss was a notable benefit across the trials, with semaglutide leading to considerable reductions regardless of initial BMI
One size will not fit all, and one size will not be best for all, Richard DiMarchi, a chemist at Indiana University who has worked on obesity drugs at both Eli Lilly and Novo Nordisk, told me
Talk to your healthcare provider before making any changes